Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. 67.71% of the stock of AbbVie is held by institutions. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. (my tables). AbbVie passed that onto its 2022 guidance. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. Enjoy your holiday weekend and catch up on our most read stories this week. According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. A AbbVie Inc. (NYSE:ABBV) insider lowered their holding by 87% earlier this year, These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio, AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says, AbbVie (NYSE:ABBV) Receives New Coverage from Analysts at Guggenheim, AbbVie to Present at the Cowen 43rd Annual Health Care Conference, AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderate to Severe Crohn's Disease, AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), 3 Stocks to Buy Right Now That Are Cash Cows, The painfully high price of Humira is patently wrong, AbbVie Inc. (NYSE:ABBV) SVP Sells $4,310,832.64 in Stock, StockNews.com Upgrades AbbVie (NYSE:ABBV) to "Strong-Buy", AbbVie Inc. (NYSE:ABBV) Director Sells $1,505,000.00 in Stock, Azita Saleki-Gerhardt Sells 25,000 Shares of AbbVie Inc. (NYSE:ABBV) Stock, AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need, view top-rated stocks among Wall Street analysts, 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. In summary, the total revenue increase of just 4% year-on-year in Q2'22 might disappoint a few investors, as might the downgraded guidance, although it is hard to argue that AbbVie is a bad investment when we consider that the Pharma also pays a dividend of $1.41 per quarter, yielding 4% per annum, drove operating earnings of $3.925bn on a GAAP basis, and trades at a >10% discount to my calculated target price. AbbVie discounted cash flow analysis. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%. Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. Remember that past performance is not a guarantee of future results and you should never invest more money than you can afford to lose. The major market events for the week ahead right in your inbox. The Abbvie stock forecast for 2025 had the price at $259.018. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. contact@marketbeat.com The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. Disclaimer. . View which stocks are hot on social media with MarketBeat's trending stocks report. To see all exchange delays and terms of use please see Barchart's disclaimer. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions). Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. Morningstar: 2019 Morningstar, Inc. All Rights Reserved. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. psoriatic arthritis at a lower dose, again with a comparable safety profile, and has also won approval in a field where Humira has not, namely Atopic Dermatitis. In the U.S. dermatology segment, where approximately 30% of patients exhibit both skin and joint involvement, Skyrizi is already achieving an in-play patient share of nearly 20%. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. AbbVie's stock is owned by many different institutional and retail investors. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. The analysts 12-month consensus ABBV stock price target was $159.75. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. Past performance is no guarantee of future results. As we can see the immunology division consists of only 3 assets yet by my calculation, will likely account for 50% of AbbVie's revenues in 2022 (to calculate 2022 sales revenues by product, since we do not yet have final figures, I have used 9m 2022 figures and assumed Q4 revenues will be the average of the previous 3 quarters). A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. Factset: FactSet Research Systems Inc.2019. The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. American Consumer News, LLC dba MarketBeat 2010-2023. 8.05% Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. How do I arrive at my share price target? These are mostly related to the US Food and Drug Administrations (FDA) approval of Abbvies drug Rinvoq for ulcerative colitis and positive top-line results from the Phase 3 induction study U-EXCEL. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. The ex-dividend date of this dividend is Thursday, April 13th. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. And it couldnt be more wrong! The lowest target is $136.35 and the highest is $210. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. Please. Please. All times are ET. CFDs are complex leveraged instruments and come with a high risk of losing money. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. The material provided on this website is for information purposes only and should not be understood as an investment advice. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. The dividend payout ratio is 89.56%. I have no business relationship with any company whose stock is mentioned in this article. AbbVie (NYSE:ABBV) has a market capitalization of $276.13 billion and generates $58.05 billion in revenue each year. ABBV currently yields 4.1% and has raised its dividend every year since 2013. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. About the AbbVie, Inc. stock forecast. The consensus among Wall Street research analysts is that investors should "hold" ABBV shares. Forecasts shouldnt be used as a substitute for your own research. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). All rights reserved. Forecast target price for 03-06-2023: $ 152.58. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. This has been in spite of a string of macroeconomic headwinds such as the ongoing Russia-Ukraine war that has contributed to record high inflation in the US and the UK, and the companys psoriatic arthritis drug Adalimumab, known as Humira, facing biosimilar rivals in the US from 2023. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. Build a CFD portfolio with your favourite companies. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Please log in to your account or sign up in order to add this asset to your watchlist. AbbVie is a leader in ESG and sustainability. My No. Although investing in AbbVie isn't riskless, it is advisable based on what we know about the company. I have no business relationship with any company whose stock is mentioned in this article. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. (AbbVie JPM Healthcare conference presentation). Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. Outside of Humira, management does not have to worry about LOEs for any of its other portfolio products before the end of the decade, which is encouraging, however, based on my own projections of how AbbVie will generate its revenues between 2023 and 2030, if management wants to drive a CAGR in the high single digits after 2025, it will need some help from its pipeline - not an area of particular strength for AbbVie. ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market. AbbVie Stock Forecast 03-06-2023. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. In this post, I will discuss Q2'22 results, as well as the long-term outlook for AbbVie based on the latest information, goals, risks, and financial modeling analysis, to try to establish a target price for AbbVie stock. Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. Our daily ratings and market update email newsletter. I'm on twitter @edmundingham. Neurology also looks strong although aesthetics, eye care and oncology have something to prove. Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. Different trading strategies will suit different investment goals with short or long-term focus. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. As such, forecasting stock prices is more of an art than a science. On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. The company also successfully completed the acquisition of Syndesi Therapeutics SA in March. Only 0.08% of the stock of AbbVie is held by insiders. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. Payout ratios above 75% are not desirable because they may not be sustainable. For the next eight years, the forecast is for Free Cash Flow to grow by . Retail sales were up but so was inflation which meant more volatility for stocks. As a result I have dropped Imbruvica revenues to just over $3.5bn in 2022 and modelled for a CAGR growth of just 1.5% between then and 2030. The difference between trading assets and CFDs. The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. Payout ratios above 75% are not desirable because they may not be sustainable. Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Having so much debt in a prevailing inflationary environment is also unattractive. These are Immunology, Oncology, Neurology, Virology and Eye Care. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. All rights reserved. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. ABBV Stock 12 Months Forecast. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. AbbVie income statement forecast (My table and assumptions). AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. Always conduct your own due diligence before investing. I am not receiving compensation for it (other than from Seeking Alpha). Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. You should do your own research and never invest money you cannot afford to lose. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. AbbVie product revenues by quarter and year since FY20. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. I wrote this article myself, and it expresses my own opinions. CNN Sans & 2016 Cable News Network. Abbvie stock price has put up an impressive performance in 2022. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". It now expects full-year profit in the range of $13.92-$14.12 a share. 2022 Cable News Network. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. While some of the gains are due to investor perception that it is a strong company, some view ABBV as a defensive stock, with most of the other stocks in the sector also doing well. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Earnings for AbbVie are expected to decrease by -0.55% in the coming year, from $11.00 to $10.94 per share. Join the 500.000+ traders worldwide that chose to trade with Capital.com, Also you can contact us: AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. Bhd., AbbVie Sp. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. As such I have modelled similar, although I have included an additional revenue stream from new products which I expect to be minor in nature but ultimately contributing an additional $1.5bn to the top line. The dividend payout ratio of AbbVie is 89.56%. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). writing - trading down slightly from its all-time high of >$160 achieved in early December last year. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. Their ABBV share price forecasts range from $140.00 to $200.00. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. You should consider whether you understand how CFDs work and can afford the risks. Wallet Investor suggested that the price could hit $300.386 in June 2027. AbbVie Inc. is a US-based biopharma company with global operations. 326 E 8th St #105, Sioux Falls, SD 57103 (844) 978-6257. High institutional ownership can be a signal of strong market trust in this company. Forecast . The Abbvie stock forecast for 2025 had the price at $259.018. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . AbbVie product revenue forecasts to 2030. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser.
Victoria Milland Biography,
Taft Ca Crime Graphics,
Articles A